Blogs about: Vegfr2
Featured Blog
GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184
GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis… more →
Kinase News
GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184
crimsoncanary wrote 1 year ago: GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exel … more →
Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 d … more →
ImClone initiate Phase II trial of IMC-1121B in ovarian cancer
crimsoncanary wrote 1 year ago: ImClone have initiated a phase II clinical trial of VEGFR-2 MAb IMC-1121B in patients with advanced … more →
Eisais Multi-Kinase VEGFR Inhibitor E7080 effective in animal models
crimsoncanary wrote 1 year ago: Eisai’s Multikinase VEGFR Inhibitor E7080 has been shown to be effective in a mammary fat pad … more →
AVEO initiate Phase Ib trial with VEGFR inhibitor AV-951
crimsoncanary wrote 1 year ago: AVEO Pharmaceuticals has initiated a Phase Ib clinical study its VEGFR 1/2/3 receptor inhibitor AV- … more →
ImClone initate Phase II trial in prostate cancer comparing IMC-A12 and IMC-1121B
crimsoncanary wrote 1 year ago: ImClone have commenced enrollment in a Phase II trial with either IMC-A12 or IMC-1121B in patients w … more →
J&J publish series of dual Aurora-A/VEGF-R2 kinase inhibitors
crimsoncanary wrote 1 year ago: J&J have published a series of 7-[1H-indol-2-yl]-2,3-dihydro-isoindol-1-one dual Aurora-A/VEGF-R … more →
ImClone initiate Phase III for Anti-VEGFR2 MAb IMC-1121B in Breast Cancer
crimsoncanary wrote 1 year ago: ImClone Systems have initiated a global Phase 3 clinical trial of VEGFR2 MAb IMC-1121B in women with … more →
Amgen publish series of Indazole KDR/VEGFR-2 Inhibitors
crimsoncanary wrote 1 year ago: Amgen have published a series of Indazole KDR/VEGFR-2 Inhibitors … more →
Exelixis MET/RET/VEGFR2 inhibitor XL184 achieves proof of concept in cancer
crimsoncanary wrote 1 year ago: Exelixis have announced that its MET/RET/VEGFR2 inhibitor XL184 has achieved proof of concept in hem … more →
Exelixis initiate Phase III trial of MET/RET/VEGFR2 inhibitor XL184 in Thyroid cancer
crimsoncanary wrote 1 year ago: Exelixis have initiated a phase III trial of MET/RET/VEGFR2 inhibitor XL184 for the treatment of med … more →
Exelixis begin Phase II trial of multikinase inhibitor XL184 in Glioblastoma Multiforme
crimsoncanary wrote 1 year ago: Exelixis are initiating a Phase II trial of XL184 for the treatment of Malignant Glioma … more →
AstraZeneca's VEGF inhibitor cediranib inhibits VEGFR3 activity as well as VEGFR1 and VGFR2
crimsoncanary wrote 1 year ago: Data published in Cancer Research show that AstraZeneca’s VEGF inhibitor Cediranib inhibits VE … more →
Exelixis prepare for Phase III trial of its Met/Ret/VEGFR2 inhibitor XL184 in medullary thyroid cancer
crimsoncanary wrote 1 year ago: Exelixis and the US FDA have reached an agreement on Phase III trial design for its Met/Ret/VEGFR2 i … more →
Novel VEGFR inhibitors described
crimsoncanary wrote 1 year ago: Researchers from Eberhard-Karls University, ProQinase GmbH and Johannes Gutenberg University describ … more →
Phase II data on Exelixis EGFR/HER2/VEGFR2 inhibitor XL647
crimsoncanary wrote 1 year ago: Phase II data presented at ASCO show Exelixis’ EGFR/HER2/VEGFR2 inhibitor XL647 to demonstrate … more →
XL184 demonstrates safety and efficacy in Phase I trial in Thyroid Cancer
crimsoncanary wrote 1 year ago: Exelixis’ MET/VEGFR2/RET inhibtor XL184 has been shown to be safe and to demonstrate efficacy … more →
Amgen present data on new kinase programs
crimsoncanary wrote 1 year ago: AMG-479 – IGF-1R MAb – Phase I results show the drug is safe when administered in combin … more →
Axitinib addition to gemcitabine chemotherapy may improve pancreatic cancer survival
crimsoncanary wrote 1 year ago: Researchers from Groupe Hospitalier Pitie-Salpetriere report that the addition of Axitinib to standa … more →
